Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

← catalyst calendar

NCT07318610 · readout in 1,094 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

7,050estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-10

actual

When the study began enrolling

Primary completion

2029-08-18

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-11-16

estimated

The whole study's end, after follow-up

First posted

2026-01-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Peripheral Artery Disease (PAD)

Interventions

Drug: REGN7508 — also filed as cenvacibart
Drug: REGN9933 — also filed as amrecibart
Drug: Placebo
Drug: Rivaroxaban

Primary outcomes

what the primary-completion date above is the date OF

Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death

measured Approximately up to 42 months

Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding

measured Approximately up to 42 months

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed